Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
08/2010
08/26/2010WO2010095768A1 4 -isopropylphenyl glucitol compounds as sgltl inhibitors
08/26/2010WO2010095767A1 Pyrimidin-4(3h)-one derivatives
08/26/2010WO2010095766A1 1,4-benzodiazepin-2-on derivatives
08/26/2010WO2010095753A1 Novel compound, phosphorylation inhibitor, insulin resistance improving agent, agent to prevent or to treat diabetes, and screening method
08/26/2010WO2010095663A1 Fused heterocyclic ring compound
08/26/2010WO2010095462A1 Novel compounds comprising a 3-(5-alkoxypyrimidin-2-yl) pyrimidin-4(3h)-one structure and drugs that comprise same
08/26/2010WO2010095096A1 Use of vgii3 activity modulator for the modulation of adipogenesis
08/26/2010WO2010094120A1 Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
08/26/2010WO2010077635A3 Heat moisture treated carbohydrates and uses thereof
08/26/2010WO2010066682A4 Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
08/26/2010WO2010062861A9 Bile acid recycling inhibitors for treatment of obesity and diabetes
08/26/2010WO2010049678A3 Treatment of energy utilization diseases
08/26/2010WO2010015816A3 Treatment of lysosomal storage disorders and other proteostatic diseases
08/26/2010US20100217727 Dopamine Transporter Inhibitors for Use in Treatment of Movement Disorders and Other CNS Indications
08/26/2010US20100216886 Polymorphs of n2-(1,1'-biphenyl-4-ylcarbonyl)-n1-[2-(4-fluorophenyl)-1,1-dimethylethyl]-l-alpha-glutamine
08/26/2010US20100216884 Nitrated-fatty acids modulation of type ii diabetes
08/26/2010US20100216871 Use of compounds having ccr antagonism
08/26/2010US20100216866 RNAi Modulation of APOB and Uses Thereof
08/26/2010US20100216864 RNA Antagonist Compounds for the Modulation of PCSK9
08/26/2010US20100216861 Amino arylsulfonamide compounds and their use as 5-ht6 ligands
08/26/2010US20100216853 Methods and Compositions for Modulating P300/CBP Activity
08/26/2010US20100216848 Liquid pharmaceutical compositions for parenteral administration of a substituted amide
08/26/2010US20100216833 Tetrahydrocarbazoles and derivatives
08/26/2010US20100216832 Method for Assaying FTO (2-Oxoglutarate Dependent Oxygenase) Activity
08/26/2010US20100216827 Aryl gpr120 receptor agonists and uses thereof
08/26/2010US20100216821 Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists
08/26/2010US20100216820 Thienopyrimidiones for treatment of inflammatory disorders and cancers
08/26/2010US20100216818 Inhibitors of Post-Amadori Advanced Glycation End Products
08/26/2010US20100216812 Cyclopropyl Amide Derivatives
08/26/2010US20100216809 Piperidine/piperazine derivatives
08/26/2010US20100216800 Treatment of Type 2 Diabetes With a Combination of DPIV Inhibitor and Metformin or Thiazolidinedione
08/26/2010US20100216794 Pyridine derivatives useful as glucokinase activators
08/26/2010US20100216785 Pharmaceutical compositions
08/26/2010US20100216781 mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY
08/26/2010US20100216765 Kinase inhibitors
08/26/2010US20100216764 Soluble Guanylate Cyclase Activators
08/26/2010US20100216758 Pyridone Compounds
08/26/2010US20100216756 Compositions and methods for suppressing endometrial proliferation
08/26/2010US20100216729 Cancer cell growth inhibition by black bean (Phaseolus vulgaris L) extracts
08/26/2010US20100216726 Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof
08/26/2010US20100216724 Use of fibronectin fragment (196-203 ) as a therapeutic agent
08/26/2010US20100216722 Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent
08/26/2010US20100216716 Cell-Permeable Peptide Inhibitors Of The JNK Signal Transduction Pathway
08/26/2010US20100216715 FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use
08/26/2010US20100216701 Protein Kinase C Inhibitors for Prevention of Insulin Resistance and Type 2 Diabetes
08/26/2010US20100216694 Antidiabetic tricyclic compounds
08/26/2010US20100216693 Compositions and methods of treating diabetes
08/26/2010US20100216692 Acidic Insulin Preparations Having Improved Stability
08/26/2010US20100216691 Protease Stabilized, Pegylated Insulin Analogues
08/26/2010US20100216690 Pegylated Single-Chain Insulin
08/26/2010US20100215782 Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis
08/26/2010US20100215779 Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention
08/26/2010US20100215769 Natural occurring nutrient supplement compositions and methods of treatment using same by improving resistance to DNA damage, enhancing DNA repair and stimulating immune function wherein metabolic competition is avoided
08/26/2010US20100215761 Composition for regulating lipid metabolism
08/26/2010US20100215760 Intrinscially fluorescent carbon nanospheres and a process thereof
08/26/2010US20100215759 Pharmaceutical compounds
08/26/2010US20100215752 Policosanol nanoparticles
08/26/2010US20100215741 Pharmaceutical compounds
08/26/2010US20100215739 Low dose topiramate / phentermine composition and methods of use thereof
08/26/2010US20100215732 Ingestible implement for weight control
08/26/2010US20100215689 Soluble Fiber Combinations for Weight Control and Improving Parameters of Cardiovascular Health
08/26/2010US20100215688 Compositions for suppressing obesity
08/26/2010US20100215677 Pdz domain interactions and lipid rafts
08/26/2010US20100215676 Kdr peptides and vaccines comprising the same
08/26/2010US20100215667 Methods and compositions of treatment for modulating the immune system of animals
08/26/2010US20100215665 Mixed lineage kinases and metabolic disorders
08/26/2010US20100215661 Nicotinamide derivates useful as p38 inhibitors
08/26/2010US20100215655 Angiogenesis-inhibiting chimeric proteins and the use
08/26/2010US20100215652 Nicotinamide derivates useful as p38 inhibitors
08/26/2010US20100215635 Small molecules to induce weight loss or to reduce weight gain
08/26/2010US20100215614 Enterostatin as Inhibitor of Angiogenesis
08/26/2010CA2752845A1 Use of vgii3 activity modulator for the modulation of adipogenesis
08/26/2010CA2752739A1 1,4-benzodiazepin-2-on derivatives
08/26/2010CA2752212A1 4-isopropylphenyl glucitol compounds as sgltl inhibitors
08/26/2010CA2751244A1 Pyrimidin-4(3h)-one derivatives
08/26/2010CA2750564A1 Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
08/25/2010EP2221307A1 Purine derivatives as adenosine A1 receptor agonists and methods of use thereof
08/25/2010EP2221301A1 Heteroaryloxy quinazoline derivative
08/25/2010EP2221066A1 Use of VgII3 activity modulator for the modulation of adipogenesis
08/25/2010EP2221065A1 Therapeutic or prophylactic agent, detection method and detection agent for metabolic syndrome, and method for screening of candidate compound for therapeutic agent for metabolic syndrome
08/25/2010EP2221059A1 Composition for reducing the level of glucose, malondialdehyde-modified ldl, homocysteine and/or c-reactive protein in blood
08/25/2010EP2221052A2 Compositions that treat or inhibit pathological conditions associated with inflammatory response
08/25/2010EP2221051A1 Amine derivative having npy y5 receptor antagonist activity and use thereof
08/25/2010EP2221047A1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
08/25/2010EP2220103A1 Novel mangiferin calcium salts, the method for its preparation and its use
08/25/2010EP2220052A1 Cyclic urea inhibitors of 11 -hydroxysteroid dehydrogenase 1
08/25/2010EP2220048A2 Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
08/25/2010EP2220040A1 New crystalline diphenyl acetidinone hydrate, pharmaceutical agent containing said compound and use thereof
08/25/2010EP2220037A1 Synthetic sphingolipid analogs
08/25/2010EP2219664A1 Methods for treating obesity and obesity related diseases and disorders
08/25/2010EP2219652A2 Phospholipid compositions and uses thereof
08/25/2010EP2219627A2 Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction
08/25/2010EP1898724B1 Infant nutrition with hydrolised proteins
08/25/2010EP1716132B1 Spiro-benzodioxoles and their use as cb1 antagonists
08/25/2010EP1641792B1 Pyrrolodihydroisoquinolines as pde10 inhibitors
08/25/2010EP1551834B1 Substituted quinazolinone compounds
08/25/2010EP1517892B1 Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof
08/25/2010EP1366016B1 Process for the preparation of arylethanoldiamines useful as agonists of the beta-3-adrenoceptor
08/25/2010EP1363632B1 Receptor selective cannabimimetic aminoalkylindoles
08/25/2010EP1339402B1 Azaphenanthridone derivatives and their use as parp inhibitors
1 ... 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 ... 1298